Roivant Sciences (ROIV)
35.01
-0.09 (0.26%)
Upcoming Events
Latest Headlines
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026 4:05 PM - StreetInsider
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026 4:05 PM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Epperly Melissa B,
July 21, 2026 9:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Oren Ilan
July 21, 2026 9:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: MOMTAZEE JAMES C
July 21, 2026 9:00 PM - SEC Filing
Arbutus sues Pfizer and BioNTech over LNP patents in 3 countries
July 16, 2026 7:30 AM - StreetInsider
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to
July 16, 2026 7:30 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Gline Matthew
July 2, 2026 7:06 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Fitzgerald Meghan
July 2, 2026 7:04 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Torti Frank
July 2, 2026 7:01 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Sukhatme Mayukh
July 2, 2026 7:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 29 Filed by: Epperly Melissa B,
July 1, 2026 6:34 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 26 Filed by: MANCHESTER KEITH S
June 30, 2026 8:38 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 26 Filed by: Gold Daniel Allen
June 30, 2026 8:30 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 26 Filed by: QVT Financial LP
June 30, 2026 7:59 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Fitzgerald Meghan
June 30, 2026 4:36 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: MANCHESTER KEITH S
June 30, 2026 4:26 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 25 Filed by: Sukhatme Mayukh
June 29, 2026 6:23 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Epperly Melissa B,
June 29, 2026 4:41 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 24 Filed by: Venker Eric
June 26, 2026 6:14 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
June 26, 2026 4:10 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
June 25, 2026 4:34 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
June 24, 2026 4:01 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 20 Filed by: Pulik Richard
June 23, 2026 9:18 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 20 Filed by: Humes Jennifer
June 23, 2026 9:16 PM - SEC Filing
Roivant Sciences (ROIV) PT Raised to $36 at Guggenheim
May 26, 2026 6:38 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Venker Eric
May 22, 2026 6:26 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Pulik Richard
May 22, 2026 6:22 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
May 22, 2026 4:01 PM - SEC Filing
Piper Sandler on Roivant Sciences (ROIV): 'Mosliciguat Ph2 PHocus Takes Center Stage & Catalyst-Rich 2026'
May 21, 2026 9:00 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $40 at Bernstein SocGen Group
May 21, 2026 8:55 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised at TD Cowen as 'IMVT-1402 Shines In D2T RA'
May 21, 2026 7:59 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
May 21, 2026 6:37 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $42 at Leerink
May 21, 2026 6:20 AM - StreetInsider
Form S-8 Roivant Sciences Ltd.
May 20, 2026 4:40 PM - SEC Filing
Form 10-K Roivant Sciences Ltd. For: Mar 31
May 20, 2026 7:17 AM - SEC Filing
Form 8-K Roivant Sciences Ltd. For: May 20
May 20, 2026 7:14 AM - SEC Filing
Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c
May 20, 2026 7:08 AM - StreetInsider
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: MORGAN STANLEY
May 12, 2026 1:20 PM - SEC Filing
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026 4:05 PM - StreetInsider
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
May 11, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: Ramaswamy Vivek
May 6, 2026 9:07 PM - SEC Filing
Full Article List